Table 4.
Safety profile (any adverse events with incidence > 1%)
| RAD (n=146) | PAD (n=145) | p-value | |
|---|---|---|---|
| Leukopenia | 35 (24.0) | 38 (26.1) | > 0.05 |
| Neutropenia | 41 (28.1) | 46 (31.6) | > 0.05 |
| Febrile neutropenia | 12 (8.3) | 9 (6.2) | > 0.05 |
| Anemia | 30 (20.6) | 29 (19.9) | > 0.05 |
| Thrombocytopenia | 21 (14.4) | 17 (11.7) | > 0.05 |
| Anorexia | 43 (29.5) | 47 (32.2) | > 0.05 |
| Mucositis | 14 (9.6) | 19 (13.1) | > 0.05 |
| Diarrhea | 18 (12.4) | 13 (9.0) | > 0.05 |
| Abdominal pain | 9 (6.2) | 7 (4.8) | > 0.05 |
| Constipation | 24 (16.5) | 26 (17.9) | > 0.05 |
| Alopecia | 27 (18.5) | 40 (27.4) | > 0.05 |
| Rash | 4 (2.8) | 4 (2.8) | > 0.05 |
| AST elevation | 5 (3.5) | 5 (3.5) | > 0.05 |
| ALT elevation | 6 (4.2) | 4 (2.8) | > 0.05 |
| Hypernatremia | 8 (5.5) | 11 (7.6) | > 0.05 |
| Hyperkalemia | 12 (8.3) | 13 (9.0) | > 0.05 |
| Hypercalcemia | 8 (5.5) | 8 (5.5) | > 0.05 |
| Hypophosphatemia | 9 (6.2) | 5 (3.5) | > 0.05 |
Values are presented as number (%). Adverse events were graded according to National Cancer Institute–Common Terminology Criteria (CTCAE) ver. 4.03. RAD, ramosetron, aprepitant, and dexamethasone; PAD, palonosetron, aprepitant, and dexamethasone; AST, aspartate aminotransferase; ALT, alanine aminotransferase.